Living Donor Liver Transplantation With Augmented Venous Outflow and Splenectomy: A Promised Land for Small Left Lobe Grafts: Erratum

In the November 2022 issue of Annals of Surgery, a correction was needed in the article by Fujiki et al., “Living Donor Liver Transplantation With Augmented Venous Outflow and Splenectomy: A Promised Land for Small Left Lobe Grafts.”

In the first paragraph of the “Graft and Patient Survival” section, the percentage rates for Figure 2 were reported incorrectly. They should be as follows:

Figure 2 shows no difference in graft survival based on graft type (LLG (H1234-MHV) 1, 3, 5-yr survival (92%, 88%, 78%) vs. RLG (H5678) (96%, 91%, 85%), P= 0.97) or splenectomy status (with splenectomy 1, 5-yr survival (94%, 84%) vs. without splenectomy 1, 5-yr survival (93%, 81%), P=0.52). Importantly, small grafts with GRWR ≤0.7% (n= 28) had comparable graft survival compared to grafts with GRWR >0.7% (n=102) (1, 3, 5-yr survival (93%, 93%, 93%) vs. (94%, 88%, 80%), P=0.21).

The authors apologize for this error.

1. Fujiki M, Hashimoto K, Quintini C, et al. Living Donor Liver Transplantation With Augmented Venous Outflow and Splenectomy: A Promised Land for Small Left Lobe Grafts. Ann Surg. 2022;276:838–845.

留言 (0)

沒有登入
gif